Prestige Consumer Healthcare (NYSE:PBH) Raised to “Buy” at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

A number of other analysts also recently issued reports on the company. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. DA Davidson lifted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, Canaccord Genuity Group increased their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $92.60.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $83.71 on Tuesday. The company has a market cap of $4.15 billion, a P/E ratio of 19.61, a P/E/G ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a twelve month low of $62.35 and a twelve month high of $90.04. The company’s 50-day moving average price is $82.06 and its 200-day moving average price is $78.49. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kestra Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC boosted its holdings in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after acquiring an additional 152 shares during the period. Headlands Technologies LLC acquired a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $40,000. Huntington National Bank increased its stake in Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares during the period. Finally, McIlrath & Eck LLC lifted its position in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.